Table 1.

Summary of SHIV bNAb Passive Protection Studies in Macaques

Region of Env	Antibody	SHIV(Route) Tier(Clade)	Challenge dose (TCID50)		mAb dose (mg/kg)	IC50 (Mg/ml)/ Neutralization Assay	TOC serum concentration (Mg/ml)	Fold >IC50	No. Protected /Total	Protective Efficacy (percent)	Ref.
CD4bs	b12	SF162P4(IVAG) Tier 1(B)	300		25	1.0/rhPBMC	705	705	4/4	100	[51]
					5		149	149	2/4	50
					1		16	16	0/4	0
		SF162P3(IVAG) Tier 2(B)	300		25	1.6/rhPBMC	563	352	8/9	89	[152]
	VRC01	SF162P3(IVAG) Tier 2(B)	300		20	1.86/TZM-bl	65	35	4/4	100	[50]
		SF162P3(IR) Tier 2(B)			20		79	42	4/4	100
		BAL(IR) Tier 1(B)	12,800		20	0.02	61	3,050	6/6	100	[153]
					5		22	1,100	6/6	100
					0.3		1.3	65	4/10	40
		AD8EO(IR) Tier 2(B)	1,000		50	0.94/TZM-bl	649	690	1/2	50	[153]
					20		197.3	210	0/2	0
		DH12-V3AD8 Tier 2(B)			30	2.35	350.9	149	1/2	50
	3BNC117	AD8EO(IR) Tier 2(B)	1,000		5	0.14/TZM-bl	91	650	2/2	100	[153]
					1		27.35	195
		DH12-V3AD8 Tier 2(B)			20	0.14/TZM-bl	283.8	2,027	2/2	100
					5		123.85	885	1/2	50
					1		26.45	650	1/2	50
					0.2		4.8	195	0/2	0
V2	CAP256-VRC26.25	325c(IVAG) Tier2(C )	500		2	0.003/TZM-bl	20	6,667	4/4	100	[53]
					0.4		2.5	833
					0.08		0.75	250
	PGDM1400		500		2	0.037/TZM-bl	7.5	203	4/5	80
					0.4		2	54	5/5	100
					0.08		0.2	5.4	1/4	25
V1V2	PG9	BAL.P4(IR) Tier 1(B)	12,800		20	0.06/TZM-bl	32	533	4/6	67	[50]
					5		3.7	62	3/6	50
					0.3		0.28	5	0/6	0
V3 glycan	PGT121	SF162P3(IVAG) Tier 2(B)	300		5	0.005/TZM-bl	95	19,000	5/5	100	[49]
				1			15	3,000	3/5	60
				0.2			1.8	360	0/5	0
		AD8EO(IR) Tier 2(B)	1,000	20		0.1/TZM-bl	260.75	2,608	2/2	100	[153]
				5			51.45	515	1/2	50
				1			21.85	219	2/2	100
				0.2			L8	18	0/2	0
		DH12-V3AD8(B)	1,000	20		0.01/TZM-bl	207.9	20,790	4/4	100
				1			22.2	2,220	1/2	50
				0.2			2.35	235	2/2	100
				0.05			1.15	115	0/2	0
	PGT126	SF162P3(IVAG) Tier 2(B)	300	10		0.03/TZM-bl	98	3,267	5/5	100	[154]
				2			20	667	2/5	40
				0.4			3.6	120	1/5	20
		SF162P3(IR) Tier 2(B)		10			130	4,333	3/4	75
				2			27	900	2/4	50
				0.4			4.8	160	0/4	0
	10–1074	AD8EO(IR) Tier 2(B)	1,000	20		0.15/TZM-bl	273.75	1,825	2/2	100	[153]
				5			768	768	2/2	100
				1			149	149	0/2	0
				20		0.06/TZM-bl	231.8	3,863	2/2	100
				5			95.95	1,599	2/2	100
				1			23.5	392	1/2	50
				0.2			19.55	326	0/2	0
Man-9glycans	2G12	SF162P3(IR) Tier 2(B)	500	40		7.6/TZM-bl	1053	139	3/5	60	[155]
						200/rhPBMC		53
MPER	10E8	BAL.P4(IR) Tier 1(B)	12,800	20		0.57/TZM-bl	133	233	6/6	100	[50]
				5			31	54	6/6	100
				0.3			1.8	3	3/6	50
	4E10	BAL(IR) Tier 1(B)	2,000	50		0.8/TZM-bl	866	1,125	6/6	100	[156]
						6.0/rhPBMC		144
	2F5	BAL(IR) Tier 1(B)	2,000	50		0.4/TZM-bl	742	1,855	6/6	100
						3.0/rhPBMC		247